SODIUM NITROPRUSSIDE FOR INJECTION 25 MG
SODIUM NITROPRUSSIDE : 25 MG · DIN 02450089 · STERIMAX INC
Health Canada status: MARKETED
What is SODIUM NITROPRUSSIDE FOR INJECTION?
SODIUM NITROPRUSSIDE FOR INJECTION 25 MG contains SODIUM NITROPRUSSIDE : 25 MG. It is listed in the Health Canada Drug Product Database under DIN 02450089, held by STERIMAX INC, supplied as SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 26-Apr-2021. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is SODIUM NITROPRUSSIDE FOR INJECTION used for?
Treatment of acute hypertension refractory to standard measures; producing controlled hypotension during anesthesia to reduce bleeding in surgical procedures.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02450089 |
|---|---|
| Brand name | SODIUM NITROPRUSSIDE FOR INJECTION |
| Generic / active ingredient | SODIUM NITROPRUSSIDE : 25 MG |
| Manufacturer | STERIMAX INC |
| Strength | 25 MG |
| Dosage form | SOLUTION |
| Route of administration | INTRAVENOUS |
| Schedule | Prescription |
| ATC code | C02DD01 NITROPRUSSIDE |
| AHFS class | 24:08.20 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 26-Apr-2021 |
| Original market date | 2021-04-26 00:00:00 |
How is it administered?
Must be diluted in 5% Dextrose. Average dose 3 mcg/kg/min (range 0.5-8 mcg/kg/min). Administer via infusion pump. Do not exceed 8 mcg/kg/min for more than 10 minutes.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Store at controlled room temperature (15-30°C). Protect from light. Reconstituted/diluted solution stable for 24 hours.
How is it supplied?
Single-use amber glass vials in 50 mg/2 mL format (25 mg/mL). Includes supplied opaque sleeve for light protection.
Contraindications
Hypersensitivity; compensatory hypertension; physically poor-risk patients (ASA Risk 5); uncorrected anemia/hypovolemia; inadequate cerebral circulation; liver/severe renal disease (for anesthesia).
Warnings and precautions
Serious Warning: Not for direct injection. Can cause precipitous BP decrease and fatal cyanide poisoning. Monitor acid-base balance. Discontinue if resistance/tachyphylaxis occurs.
What can be used instead?
Other Canadian products sharing ATC code C02DD01 NITROPRUSSIDE. 4 of 6 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| SODIUM NITROPRUSSIDE FOR INJECTION | 25 MG | SOLUTION | MARCAN PHARMACEUTICALS INC | MARKETED | DIN 02479109 |
| SODIUM NITROPRUSSIDE FOR INJECTION | 25 MG | SOLUTION | DR REDDY'S LABORATORIES LTD | MARKETED | DIN 02507404 |
| SODIUM NITROPRUSSIDE FOR INJECTION | 25 MG | SOLUTION | JAMP PHARMA CORPORATION | MARKETED | DIN 02542129 |
| NIPRIDE | 25 MG | SOLUTION | PFIZER CANADA ULC | CANCELLED POST MARKET | DIN 02361736 |
| NIPRIDE | 50 MG | POWDER FOR SOLUTION | HOSPIRA HEALTHCARE ULC | CANCELLED POST MARKET | DIN 00336459 |
Who else supplies NITROPRUSSIDE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. NITROPRUSSIDE appears in 5 registered pack listings across 3 markets, published on 3 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.